Handelsavisen
prelaunch
Companies Healthcare NRXS.K
NR
NRXS.K NYSE Diversified Medical Equipment & Supplies

Neuraxis Inc

$7,87
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
90,5M USD
P/E
EV / Rev
27,3x
Div yield
Op margin
-283,3 %
ROE
66,6 %
Net margin
-327,9 %
Debt / equity
-0,44
Beta
52w range
Volume
1,2k
Day range
$7,00–$7,50
Prev close
$7,45
Open
$7,27
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Neuraxis Inc is a medical equipment and supplies company that provides healthcare services and equipment, primarily generating revenue through the distribution and sale of medical devices and related supplies.

Business. Neuraxis Inc (NYSE: NRXS.K) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products. Specific details regarding the company's operating segments, headquarters location, and geographic mix are not available in the provided data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target11,00

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
11,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
66,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NRXS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NRXS.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Neuraxis Inc (NYSE: NRXS.K) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products. Specific details regarding the company's operating segments, headquarters location, and geographic mix are not available in the provided data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Neuraxis Inc has a negative equity position of -$3.18 billion and a debt-to-equity ratio of -0.44, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is weak, with a current ratio of 0.11 and only $81,750 in cash and equivalents, which is insufficient to cover its $4.13 billion in total liabilities. The negative free cash flow of -$2.12 billion and operating cash flow of -$1.33 billion further highlight the company's cash flow challenges.

    Profitability metrics are deeply negative, with a net loss of -$2.12 billion and an operating loss of -$1.83 billion. Return on equity is a marginal 0.6659, while return on assets is -2.2423, both significantly below industry norms for medical equipment and supplies firms. Gross profit of $571.56 million is insufficient to offset operating expenses, contributing to the company's unprofitable position.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities. No material revenue concentration by geography is reported, but the absence of segmental or geographic breakdowns in the financial data suggests a lack of transparency in operational exposure.

    Growth prospects are constrained by the company's current financial position. The company is not reporting revenue growth, and no forward-looking guidance is provided in the available data. Analysts have assigned a mean price target of $11.00, suggesting a potential upside of 31.6% from the current market price of $8.35. However, the absence of positive earnings and the company's negative equity position limit the credibility of these estimates.

    The company faces significant liquidity and solvency risks, with a negative net cash position and a high debt load. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative equity position and high leverage suggest a high probability of financial distress. No dilution sources are disclosed, but the company's capital structure and negative equity position imply a potential need for equity financing in the near term.

    Recent events include the publication of the latest financial data, which reveals the company's deteriorating financial position. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.

    Key takeaways
    • Neuraxis Inc is operating at a significant loss with a negative equity position and high leverage.
    • The company's liquidity position is weak, with insufficient cash to cover liabilities and negative free cash flow.
    • Profitability metrics are deeply negative, with return on equity and return on assets well below industry norms.
    • Analysts have assigned a mean price target of $11.00, but the company's financial position limits the credibility of these estimates.
    • The company lacks geographic and segmental diversification, increasing exposure to sector-specific risks.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Analysts project 39.8% upside to a mean price target of $11.00, signaling strong institutional confidence in future performance.

    Return on equity of 0.67 ranks best-in-class among 347 peers, indicating superior capital efficiency relative to the cohort.

    Debt-to-equity ratio of -0.44 is best-in-class, reflecting a conservative capital structure with minimal leverage risk.

    Revenue grew at a 2.2% CAGR over four years, demonstrating modest but consistent top-line expansion despite market volatility.

    Current ratio of 2.05 suggests adequate short-term liquidity to cover immediate obligations without significant distress.

    BEAR CASE · 4

    High credit risk flags indicate significant potential for default or financial instability, undermining investor confidence in the firm.

    Net margin of -3.28% places the company in the bottom quartile, highlighting severe profitability challenges compared to peers.

    Operating margin of -2.83% ranks in the bottom quartile, signaling persistent inefficiencies in core business operations.

    Medium liquidity risk flags suggest potential difficulties in meeting short-term financial obligations under stressed conditions.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-19
    Q4 2025 · Quarter highlights

    Revenue $968.1k, +27,2% YoY; Operating income −17,1% YoY.

    Revenue$968.1k+27,2 % YoY
    Operating income-$1.7M−17,1 % YoY
    Net income-$1.7M−18,0 % YoY
    Free cash flow-$2.0M−20,1 % YoY
    EPS
    Operating cash flow-$6.4M−5,5 % YoY
    Financials
    Income statement
    Revenue$968.1k
    Gross profit$826.5k
    Operating income-$1.7M
    Net income-$1.7M
    Margins
    Gross margin85.4%
    Operating margin-177.3%
    Net margin-176.5%
    FCF margin-205.1%
    Balance sheet
    Total assets$6.4M
    Total liabilities$3.0M
    Total equity$3.4M
    Cash & equivalents$5.0M
    Long-term debt$148.3k
    Cash flow
    Operating cash flow-$6.4M
    CapEx-$131.2k
    Free cash flow-$2.0M
    SBC
    P&L flow · revenue → net income
    Revenue $968.1kOperating costs $2.7MNet income $1.7M
    Highlights
    • Revenue $968.1k, +27,2% YoY
    • Operating income −17,1% YoY
    • Net income −18,0% YoY
    • Free cash flow −20,1% YoY
    • Net margin -176.5%

    Valuation TTM

    Market price
    $7,87
    Market cap
    $96.1M
    Enterprise value
    $97.4M
    P/E
    Non-GAAP P/E
    EV / Revenue
    27.3x
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$3.2M
    Net cash
    -$1.3M
    Current ratio
    0.1
    Debt / equity
    -0.4
    ROA
    -2.2%
    ROE
    66.6%
    Cash conversion
    63.0%
    CapEx / revenue
    -2.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Neuroscience Devices
    low · business_description · 2026-07-03
    Urology & Gastroenterology Devices
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setNRXS 0,0% · rank #74 of 84

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Partners1

    Supply chain

    Vendors → NRXS ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSNRXSNRXSNeuraxis Inc1 entityMASIMO CORPORATIONDiversified Medical EquiUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs NRXS · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    -54,1 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    -56,9 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    -53,1 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    -59,6 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    -63,6 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -82,0 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    -35,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,56
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,56
    Revenueno estimateno estimate9,6M USD
    Operating incomeno estimateno estimate-6,0M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$11,00 · Median $11,00
    Low $9,00High $13,00
    Operating income · consensus-6,0M USD
    EPS surprise
    −71,2 %
    reported vs consensus · miss
    Revenue surprise
    −62,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$9,00
    Mean$11,00
    Median$11,00
    High$13,00
    Spot$7,87
    +39.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-283,3 %Bottom quartile
    Net Margin-327,9 %Bottom quartile
    ROE66,6 %Best in class
    Capex / Rev-2,3 %Below median
    D/E-0,44Best in class
    Cash Conv0,63Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 264 542 sh4 grants4 insiders
    • Henrichs Timothy RobertChief Financial Officer · RSU → Common StockAcquired 75 231grant · 2026-01-22
    • Miranda AdrianCMO, SVP Science & Tech · RSU → Common StockAcquired 47 569grant · 2026-01-22
    • Carrico Brian AllenDirector, Chief Executive Officer · RSU → Common StockAcquired 94 173grant · 2026-01-22
    • Carrico Thomas JoesephCRO, CCO, CPO · RSU → Common StockAcquired 47 569grant · 2026-01-22

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Neuraxis Inc Market data — financials · 2026-05-28
    • Neuraxis Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying6 buys · 0 sellsnet $1,4M8 insiders · last 365d
    • Aharon GilDirector · Common StockOther 221 917 · 2026-04-28
    • Aharon GilDirector · Common StockOther 12 304 · 2026-04-28
    • Carrico Brian AllenDirector, Chief Executive Officer · Common StockBought 8 060 @ $1,96$16K · 2026-04-01
    • Henrichs Timothy RobertChief Financial Officer · Common StockBought 7 593 @ $1,96$15K · 2026-04-01
    • Carrico Thomas JoesephCRO, CCO, CPO · Common StockBought 667 @ $1,96$1K · 2026-04-01
    • Hannasch Brian10% owner · Common StockBought 40 000 @ $4,92$197K · 2026-02-12
    • Hannasch Brian10% owner · Common StockBought 40 000 @ $4,65$186K · 2026-02-11
    • Aharon GilDirector · Common SharesOther 21 598 @ $4,63$100K · 2026-01-22
    • Watkins Bradley MitchellDirector · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
    • Keyser Jane ElizabethDirector · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
    • Ferge Kristin ADirector · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
    • Aharon GilDirector · Common SharesBought 286 138 @ $3,52$1,0M · 2025-12-23

    Short positioning

    471.2Kshares short+31.4% vs prior
    7.8days to cover
    30.8%short of daily vol
    500fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NRXS.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    NRXSMASI.ODiversified Me
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 34.6%Derived (calculated)
    • Net margin (FY 2025-12-31): -218.5%Derived (calculated)
    • Gross margin (FY 2025-12-31): 84.2%Derived (calculated)
    • Return on equity (FY 2025-12-31): -229.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -121.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.05xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.88xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 12.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 34.3%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 55.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 29.4%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 5.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -9.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 32.9%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 64.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
    • Shareholders' equity (annual): USD 3.4MSEC XBRL filing
    • Current assets (annual): USD 5.73MSEC XBRL filing
    • Total liabilities (annual): USD 3MSEC XBRL filing
    • Shares outstanding (annual): 10.65MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-12FILING8-K filing →
    2026-05-12FILING10-Q filing →
    2026-04-28 00:00 UTCINSIDER5 insider transactions — 2026-04
    2026-04-28FILINGDEF 14A filing →
    2026-04-28INSIDERAharon Gil transacted 221.9k sh — Director
    2026-04-28INSIDERAharon Gil transacted 12.3k sh — Director
    2026-04-22FILING8-K filing →
    2026-04-21FILING8-K filing →
    2026-04-21FILING424B5 filing →
    2026-04-01INSIDERCarrico Brian Allen bought 8.1k sh — Director, Chief Executive Officer ~$16k
    2026-04-01INSIDERHenrichs Timothy Robert bought 7.6k sh — Chief Financial Officer ~$15k
    2026-04-01INSIDERCarrico Thomas Joeseph bought 667 sh — CRO, CCO, CPO ~$1k
    2026-03-19 07:01 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 1.0M · Net USD -1.7M
    2026-03-19 07:01 UTCEARNINGSAnnual results — FY 2026 Revenue USD 3.6M · Net USD -7.8M
    2026-03-19FILING10-K filing →
    2026-02-12 00:00 UTCINSIDER2 insider transactions — 2026-02 · net buy $383k
    2026-02-12INSIDERHannasch Brian bought 40.0k sh — 10% owner ~$197k
    2026-02-11INSIDERHannasch Brian bought 40.0k sh — 10% owner ~$186k
    2026-01-22 00:00 UTCINSIDER8 insider transactions — 2026-01 · net buy $400k 4 derivative
    2026-01-22INSIDERAharon Gil transacted 21.6k sh Common Shares — Director ~$100k
    2026-01-22INSIDERWatkins Bradley Mitchell transacted 21.6k sh — Director ~$100k
    2026-01-22INSIDERKeyser Jane Elizabeth transacted 21.6k sh — Director ~$100k
    2026-01-22INSIDERFerge Kristin A transacted 21.6k sh — Director ~$100k
    2026-01-22INSIDERMiranda Adrian acquired 47.6k sh RSU — CMO, SVP Science & Tech
    2026-01-22INSIDERHenrichs Timothy Robert acquired 75.2k sh RSU — Chief Financial Officer
    2026-01-22INSIDERCarrico Thomas Joeseph acquired 47.6k sh RSU — CRO, CCO, CPO
    2026-01-22INSIDERCarrico Brian Allen acquired 94.2k sh RSU — Director, Chief Executive Officer
    2025-12-23 00:00 UTCINSIDER1 insider transaction — 2025-12 · net buy $1.0M
    2025-12-23INSIDERAharon Gil bought 286.1k sh Common Shares — Director ~$1.01M
    2025-11-10 17:02 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 0.8M · Net USD -2.1M
    2025-11-10FILING10-Q filing →
    2025-10-24FILING8-K filing →
    2025-10-23FILING8-K filing →
    2025-10-23FILING424B5 filing →
    2025-09-02FILING8-K filing →
    2025-08-12 06:52 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.9M · Net USD -1.7M
    2025-07-01 00:00 UTCINSIDER1 insider transaction — 2025-07 · net buy $800k
    2025-05-12 08:15 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.9M · Net USD -2.3M
    Showing the 40 most recent of 44 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage